NEW YORK (GenomeWeb News) – Compugen today posted a $2.4 million profit for the second quarter due entirely to the sale of $3.6 million worth of shares that it held in Evogene.

The Tel Aviv, Israel-based firm reported total revenues of $225,000 for the three-month period ended June 30, compared to revenues of $40,000 for the second quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.